Stock Market Reviews

BCAX (Bicara Therapeutics Inc.) News

Get the latest news, insights, and market updates on BCAX (Bicara Therapeutics Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
  CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company’s Board of Directors, effective June 9, 2025. “It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-sta
  Jun 11, 2025 - $BCAX
• Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
  BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that members of management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 3:20 p.m. ET. A live webcast of the presentation will be accessible through the Investor Relations section of Bic
  Jun 3, 2025 - $BCAX
• Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
  Median DOR of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in HPV-negative HNSCC Conference call and webcast today at 3:00 p.m. CT / 4:00 p.m. ET BOSTON, June 01, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors
  Jun 1, 2025 - $BCAX
• ASCO25: Merus wins in head-to-head with Bicara for head and neck cancer
  Petosemtamab is projected to reach $1.2bn in global sales by 2030, while ficerafusp alfa will reach $620 million.
  May 29, 2025 - $BCAX
• Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update
  On May 23, Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc. (NASDAQ:BCAX) while keeping the price target at $36. This comes after the company released its interim data from Phase 1/1b trial of Ficerafusp alfa, which is the company’s lead asset and a first-in-class bifunctional antibody. Bicara Therapeutics Inc. (NASDAQ:BCAX) […]
  May 27, 2025 - $BCAX
• Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients
  On May 24, analysts at Stifel reaffirmed their Buy rating and price target of $48 for Bicara Therapeutics Inc. (NASDAQ:BCAX). This follows the American Society of Clinical Oncology (ASCO) releasing abstracts after the market’s close, which sparked debates regarding competing approaches to treating 1L SCCHN. The company’s abstract provided a number of encouraging results for HPV-negative patients. […]
  May 26, 2025 - $BCAX
• Top Midday Decliners
  Bicara Therapeutics (BCAX) shares plunged 44% after the company said late Thursday that updated inte
  May 23, 2025 - $BCAX
• Sector Update: Health Care Stocks Decline Late Afternoon
  Health care stocks retreated late Friday afternoon, with the NYSE Health Care Index down 0.2% and th
  May 23, 2025 - $BCAX
• Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics
  Merus stock rocketed — and hammered Bicara — after unveiling promising new results for its experimental head-and-neck cancer treatment.
  May 23, 2025 - $BCAX
• Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting
  Company to host conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to discuss fulsome datasetBOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the publication of an abstract with updated interim data from the company’s Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab
  May 22, 2025 - $BCAX